BIOMAT Database Logo BIOMAT Database Logo

Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study. 2022

Haibo Ding, and Junjie Xu, and Jing Liu, and Qi Wang, and Jing Kang, and Xiaolin Li, and Zining Zhang, and Xiaoxu Han, and Yongjun Jiang, and Wenqing Geng, and Hong Shang
NHC Key Laboratory of AIDS Immunology, China Medical University, National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China.

We aimed to investigate the relationship between low-level viremia (LLV) and virological failure (VF), death, and non-AIDS events (NAEs). A prospective cohort study of people living with HIV (PLHIV) on antiretroviral therapy (ART) was conducted from 2011-2018 at an HIV clinic in Shenyang, China. The incidence of VF and the mortality and NAEs due to LLV were assessed. Cox proportional hazards regression was performed to investigate risk factors for VF, mortality, and NAEs. In total, 1288 patients, contributing 3915 person-years of follow-up (median follow-up, 2.5 years [interquartile range: 2-4 years]), were enrolled. Thirty-one patients (2.4%) experienced VF, 5 (0.4%) died, and 38 (3.0%) experienced NAEs. The risk of VF was significantly increased among patients with a viral load (VL) of 200-499 copies/mL (adjusted hazard ratio [aHR]: 14.92, 95% confidence interval [CI]: 5.92-37.60) or 500-999 copies/mL (aHR: 13.68, 95% CI: 3.61-51.87), but not among patients with a VL of 50-199 copies/mL (aHR: 3.10, 95% CI: 0.86-11.09). The risk of NAEs was significantly increased among patients with LLV (aHR: 7.33, 95% CI: 3.73-14.42). Compared to no LLV, a VL of 50-199 copies/mL (aHR: 4.11, 95% CI: 1.73-9.74), 200-499 copies/mL (aHR: 18.31, 95% CI: 6.66-50.33), and 500-999 copies/mL (aHR: 21.34, 95% CI: 5.69-80.01) showed higher risk of NAEs. Low-level viremia was associated with VF and NAEs. Patients with LLV, especially those with a VL ≥200 copies/mL, may need more frequent VL testing and NAE screening.

UI MeSH Term Description Entries
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D014766 Viremia The presence of viruses in the blood. Viremias
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D019562 Viral Load The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression. Viral Burden,Virus Titer,Burden, Viral,Load, Viral,Titer, Virus
D023241 Antiretroviral Therapy, Highly Active Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor. Combination Antiretroviral Therapy,HAART,Highly Active Antiretroviral Therapy,Antiretroviral Therapies, Combination,Antiretroviral Therapy, Combination,Combination Antiretroviral Therapies,Therapies, Combination Antiretroviral,Therapy, Combination Antiretroviral

Related Publications

Haibo Ding, and Junjie Xu, and Jing Liu, and Qi Wang, and Jing Kang, and Xiaolin Li, and Zining Zhang, and Xiaoxu Han, and Yongjun Jiang, and Wenqing Geng, and Hong Shang
Natural history of patients with low-level HIV viremia on antiretroviral therapy.
August 2004, AIDS patient care and STDs,
Haibo Ding, and Junjie Xu, and Jing Liu, and Qi Wang, and Jing Kang, and Xiaolin Li, and Zining Zhang, and Xiaoxu Han, and Yongjun Jiang, and Wenqing Geng, and Hong Shang
Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.
August 2011, The Journal of infectious diseases,
Haibo Ding, and Junjie Xu, and Jing Liu, and Qi Wang, and Jing Kang, and Xiaolin Li, and Zining Zhang, and Xiaoxu Han, and Yongjun Jiang, and Wenqing Geng, and Hong Shang
Association of low-level viremia with mortality among people living with HIV on antiretroviral therapy in Dehong, Southwest China: A retrospective cohort study.
January 2023, HIV medicine,
Haibo Ding, and Junjie Xu, and Jing Liu, and Qi Wang, and Jing Kang, and Xiaolin Li, and Zining Zhang, and Xiaoxu Han, and Yongjun Jiang, and Wenqing Geng, and Hong Shang
Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.
January 2012, PloS one,
Haibo Ding, and Junjie Xu, and Jing Liu, and Qi Wang, and Jing Kang, and Xiaolin Li, and Zining Zhang, and Xiaoxu Han, and Yongjun Jiang, and Wenqing Geng, and Hong Shang
Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.
November 2012, Antimicrobial agents and chemotherapy,
Haibo Ding, and Junjie Xu, and Jing Liu, and Qi Wang, and Jing Kang, and Xiaolin Li, and Zining Zhang, and Xiaoxu Han, and Yongjun Jiang, and Wenqing Geng, and Hong Shang
Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms.
January 2019, Frontiers in microbiology,
Haibo Ding, and Junjie Xu, and Jing Liu, and Qi Wang, and Jing Kang, and Xiaolin Li, and Zining Zhang, and Xiaoxu Han, and Yongjun Jiang, and Wenqing Geng, and Hong Shang
Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya.
September 2023, EClinicalMedicine,
Haibo Ding, and Junjie Xu, and Jing Liu, and Qi Wang, and Jing Kang, and Xiaolin Li, and Zining Zhang, and Xiaoxu Han, and Yongjun Jiang, and Wenqing Geng, and Hong Shang
Low-Level Viremia Predicts Virological Failure in HIV-Infected Omani Patients Receiving Antiretroviral Therapy.
January 2020, Journal of the International Association of Providers of AIDS Care,
Haibo Ding, and Junjie Xu, and Jing Liu, and Qi Wang, and Jing Kang, and Xiaolin Li, and Zining Zhang, and Xiaoxu Han, and Yongjun Jiang, and Wenqing Geng, and Hong Shang
Rate of and predicting factors for virologic failure in HIV-infected patients with persistent low-level viremia under antiretroviral therapy.
January 2015, Journal of the International Association of Providers of AIDS Care,
Haibo Ding, and Junjie Xu, and Jing Liu, and Qi Wang, and Jing Kang, and Xiaolin Li, and Zining Zhang, and Xiaoxu Han, and Yongjun Jiang, and Wenqing Geng, and Hong Shang
Prospective cohort study of the impact of antiretroviral therapy on employment outcomes among HIV clients in Uganda.
December 2013, AIDS patient care and STDs,
Copied contents to your clipboard!